Primary Central Nervous System Lymphoma

hematologic malignancy

Identifier: CI-CAN-00003730
Entity page: /cancer/primary-central-nervous-system-lymphoma ↗
Edges: 199

Neighbours: 4 genes15 drugs10 trials
Drawn: 29 of 29 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,149 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Primary Central Nervous System Lymphoma altered in cohorts of …ALTERED_INderived4 of 4
← altered in cohorts of	MYD88 37 / 86 cases (43 %) · ssm · pcnsl_msk_2024	—	—	Primary Central Nervous System Lymphoma	1	Observed	cbioportal	graph →
← altered in cohorts of	PIM1 33 / 86 cases (38 %) · ssm · pcnsl_msk_2024	—

Primary Central Nervous System Lymphoma investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 50show all (up to 200)
→ investigated in trials for	Methotrexatesmall molecule 26 trials (10 active) · roll-up of the cancer and its descendants	—	—	Primary Central Nervous System Lymphoma	26	Observed	clinicaltrials	graph →
→ investigated in trials for	Rituximabmonoclonal antibody 26 trials (11 active) · roll-up of the cancer and its descendants	—	—	Primary Central Nervous System Lymphoma	26	Observed	clinicaltrials	graph →
→ investigated in trials for	Lenalidomidesmall molecule 12 trials (5 active) · roll-up of the cancer and its descendants	—	—	Primary Central Nervous System Lymphoma	12	Observed	clinicaltrials	graph →
→ investigated in trials for	Ibrutinibsmall molecule 10 trials (5 active) · roll-up of the cancer and its descendants	—	—	Primary Central Nervous System Lymphoma	10	Observed	clinicaltrials	graph →
→ investigated in trials for	Temozolomidesmall molecule 8 trials (3 active) · roll-up of the cancer and its descendants	—	—	Primary Central Nervous System Lymphoma	8	Observed	clinicaltrials	graph →
→ investigated in trials for	Nivolumabmonoclonal antibody 4 trials (2 active) · roll-up of the cancer and its descendants	—	—	Primary Central Nervous System Lymphoma	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Obinutuzumabmonoclonal antibody 4 trials (2 active) · roll-up of the cancer and its descendants	—	—	Primary Central Nervous System Lymphoma	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Pembrolizumabmonoclonal antibody 4 trials (2 active) · roll-up of the cancer and its descendants	—	—	Primary Central Nervous System Lymphoma	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Pomalidomidesmall molecule 4 trials (2 active) · roll-up of the cancer and its descendants	—	—	Primary Central Nervous System Lymphoma	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Zanubrutinibsmall molecule 4 trials (2 active) · roll-up of the cancer and its descendants	—	—	Primary Central Nervous System Lymphoma	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Cytarabinesmall molecule 3 trials (2 active) · roll-up of the cancer and its descendants	—	—	Primary Central Nervous System Lymphoma	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Dexamethasonesmall molecule 3 trials (1 active) · roll-up of the cancer and its descendants	—	—	Primary Central Nervous System Lymphoma	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Procarbazinesmall molecule 3 trials (1 active) · roll-up of the cancer and its descendants	—	—	Primary Central Nervous System Lymphoma	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Bimiralisibsmall molecule 2 trials (0 active) · roll-up of the cancer and its descendants	—	—	Primary Central Nervous System Lymphoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Durvalumabmonoclonal antibody 2 trials (1 active) · roll-up of the cancer and its descendants	—	—	Primary Central Nervous System Lymphoma	2	Observed	clinicaltrials	graph →

Primary Central Nervous System Lymphoma investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 50show all (up to 200)

→ investigated in trials for

Methotrexatesmall molecule

26 trials (10 active) · roll-up of the cancer and its descendants

—

Primary Central Nervous System Lymphoma

Observed

Primary Central Nervous System Lymphoma studied in …STUDIED_INderived10 of 145show all (up to 200)
→ studied in	NCT07839247Phase 2 · recruiting Zanubrutinib Plus Lenalidomide for Frail Elderly Patients With Newly Diagnosed PCNSL · condition mapped ONTOLOGY_EXACT · 145 trials mapped (58 active)	—	—	Primary Central Nervous System Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07842835not yet recruiting Registry of an Integrated Longitudinal Multimodal Biospecimen Biobank for Primary CNS Lymphoma in China (CLIMB) · condition mapped ONTOLOGY_EXACT · 145 trials mapped (58 active)	—	—	Primary Central Nervous System Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06175000Phase 2 · recruiting Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response · condition mapped ONTOLOGY_EXACT · 145 trials mapped (58 active)	—	—	Primary Central Nervous System Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04688151Phase 1 · completed Rituximab, Acalabrutinib, and Durvalumab (RAD) in Primary CNS Lymphoma. · condition mapped ONTOLOGY_EXACT · 145 trials mapped (58 active)	—	—	Primary Central Nervous System Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04462328Phase 1 · active not recruiting Acalabrutinib and Durvalumab in Primary and Secondary Central Nervous System Lymphoma · condition mapped ONTOLOGY_EXACT · 145 trials mapped (58 active)	—	—	Primary Central Nervous System Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04609046Phase 1 · active not recruiting Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma · condition mapped ONTOLOGY_EXACT · 145 trials mapped (58 active)	—	—	Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System	1	Observed	clinicaltrials	graph →
→ studied in	NCT02203526Phase 1 · active not recruiting Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma · condition mapped ONTOLOGY_EXACT · 145 trials mapped (58 active)	—	—	Primary Central Nervous System Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04464200Phase 1 · active not recruiting 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers · condition mapped ALIAS · 145 trials mapped (58 active)	—	—	Primary Central Nervous System Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05036577Phase 1 · completed A Dose-escalating Pilot Study of Orelabrutinib for Newly-diagnosed PCNSL · condition mapped ONTOLOGY_EXACT · 145 trials mapped (58 active)	—	—	Primary Central Nervous System Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07185373Phase 2/Phase 3 · recruiting Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL · condition mapped ONTOLOGY_EXACT · 145 trials mapped (58 active)	—	—	Primary Central Nervous System Lymphoma	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Strongest chains